Physician profile
David Edward Cook
NPI 1538272133
$1,302.52
in general payments reported to CMS, 2019-2025
29 companies · $42.12 in 2025
The $42.12 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2020: $230 · 2021: $566 · 2022: $210 · 2024: $134 · 2025: $42.12.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $176.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $176.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $152.17 | 2020-2021 | |
| Abbvie INC. | $113.28 | 2021-2025 | |
| Lilly USA, LLC | $112.70 | 2020-2022 | |
| Mylan Specialty L.P. | $92.15 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $90.51 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $79.14 | 2020-2021 | |
| Electromed, INC. | $76.54 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $52.91 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $46.22 | 2022-2024 | |
| Pfizer INC. | $45.91 | 2021-2022 | |
| Alkermes, INC. | $44.22 | 2019-2024 | Vivitrol |
| Esperion Therapeutics, INC. | $41.40 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $36.01 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $34.58 | 2021 | |
| Dexcom, INC. | $30.81 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $29.73 | 2020-2021 | |
| Vyne Pharmaceuticals INC. | $29.00 | 2021 | |
| Sanofi-Aventis U.S. LLC | $28.68 | 2021 | |
| Neurocrine Biosciences, INC. | $28.63 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.50 | 2024 | Jardiance |
| C. R. Bard, INC. & Subsidiaries | $16.96 | 2024 | Bd Onclarity |
| Teva Pharmaceuticals USA, INC. | $15.09 | 2019 | |
| Azurity Pharmaceuticals, INC. | $13.44 | 2024 | Horizant |
| Biodelivery Sciences International, INC. | $13.27 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $12.85 | 2020 | |
| Glaxosmithkline, LLC. | $12.61 | 2021 | |
| Novo Nordisk INC | $11.74 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.29 | 2021 | |
| Amgen INC. | $11.18 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.